BioTuesdays Feature Articles | Life Sciences News

Feature

Ventripoint readies sales push of 3D heart imaging VMS+ 3.0 device

With FDA approval in October of its VMS+ 3.0 system, which turns 2D echocardiograms into MRI equivalent 3D images, Ventripoint Diagnostics (TSXV:VPT, OTCQB:VPTDF) is gearing up for a major sales and marketing program in...

November 19, 2019

Feature

Spring Bank heading into data-rich 2020

Spring Bank Pharmaceuticals (NASDAQ:SBPH) will be reporting clinical data readouts throughout 2020 as it advances a portfolio of three drug candidates for the treatment of chronic hepatitis B virus (HBV) as well as...

November 12, 2019

Feature

Lobo Genetics enabling personalized cannabis product selection based on consumers’ genes

Closely-held Lobo Genetics is taking its cannabis genetic profile testing to the next level. “We started with genetic tests and genetic profiling and now we are complementing that by helping guide consumers to the right...

November 5, 2019

Feature

Soricimed’s platform of unique peptides making waves in cancer and beyond

Closely-held Soricimed Biopharma has developed a first-in-class platform of synthetic peptides whose various targets include an “oncochannel” implicated in the development and progression of many forms of cancer.

October 29, 2019

Feature

Salarius Pharmaceuticals targeting epigenetic causes of cancers

Salarius Pharmaceuticals (NASDAQ:SLRX) is poised to ride the growing epigenetic wave with a differentiated lead drug candidate, seclidemstat, in early clinical development for the treatment of Ewing sarcoma and advanced...

October 22, 2019

Feature

KemPharm sees license deal, debt restructuring as transformative events

KemPharm (NASDAQ:KMPH) hit a home run last month when it inked a transformative licensing deal of up to $493-million with an affiliate of Gurnet Point Capital, a private equity firm focused on the life science sector...

October 15, 2019

Feature

OncoSec TAVO technology aiming to reverse checkpoint inhibitor resistance

OncoSec Medical (NASDAQ:ONCS) is developing its TAVO drug candidate to enhance local delivery and uptake of DNA-based interleukin-12 (IL-12) directly into solid tumors to reverse patients’ resistance to checkpoint...

October 8, 2019

Feature

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

As a co-founder and CEO of closely-held Incuvers, an early-stage life sciences company developing a sophisticated incubator for cellular biologists, Sebastian Hadjiantoniou knows firsthand the rocky journey from...

October 1, 2019

Feature

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

INmune Bio (NASDAQ:INMB) is developing new therapies that modulate the innate immune system, the body’s first line of defense against pathogens, to treat cancer and neuroinflammation that lead to neurodegenerative...

September 24, 2019

Feature

CytoDyn developing leronlimab (PRO140) as a pipeline in a drug

CytoDyn (OTCQB:CYDY), which is in the process of filing for FDA approval for leronlimab (PRO140) in treatment-experienced HIV patients, is continuing to develop its lead drug candidate in eight metastatic solid tumors...

September 17, 2019

Feature

DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations

DelMar Pharmaceuticals (NASDAQ:DMPI) is conducting two Phase 2 clinical trials with its lead drug candidate, VAL-083, a DNA-targeting agent, in three distinct biomarker-driven glioblastoma multiforme (GMB) patient...

September 10, 2019

Feature

Interface Biologics sells Endexo surface modification business, sharpens focus on Epidel drug delivery platform

Closely-held Interface Biologics is selling its Endexo surface modification business and shifting its focus to its Epidel drug delivery technology, initially for ophthalmic indications.

September 3, 2019

Feature

Precipio aims to prevent misdiagnosis of blood-related cancers

Using a combination of advanced lab technologies, and a platform giving access to expert academic pathologists, Precipio (NASDAQ:PRPO) has staked out a unique position in its battle to prevent misdiagnosis of blood...

August 27, 2019

Feature

Beyond Air’s cylinder-free nitric oxide delivery system for respiratory conditions

Beyond Air (NASDAQ:XAIR), formerly AIT Therapeutics, is developing a proprietary nitric oxide (NO) generator and delivery system that uses NO generated from ambient air, rather than bulky cylinders, and delivers precise...

August 20, 2019

Feature

PharmAust readies pivotal trial in Australia to treat cancer in dogs

PharmAust (ASX:PAA) is gearing up to begin a pivotal Phase 2 study in Australia with its lead veterinary drug candidate, monepantel, for the treatment of lymphoma in canines, which if successful, could open the door to...

August 12, 2019

Feature

Theralase Phase 2 NMIBC clinical study could support marketing application

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) has designed its Phase 2 clinical study in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) based on FDA industry guidance issued in February 2018.

August 6, 2019

Feature

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

Hepion Pharmaceuticals (NASDAQ:HEPA), which recently changed its name from ContraVir Pharmaceuticals, is developing targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic...

July 30, 2019

Feature

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

PharmaCyte Biotech (OTCQB:PMCB) is developing cellular therapies for its lead pancreatic cancer program and for diabetes that are based on a proprietary cellulose-based live cell encapsulation technology known as a Cell...

July 23, 2019

Feature

Stifel analyst discusses emerging NASH therapeutic space

As a director and senior analyst covering the biotechnology sector at Stifel, Derek Archila combines analytic ability and industry experience. He has held executive positions covering biotechnology and specialty...

July 12, 2019

Feature

Ocutrx augmented reality headset helping AMD patients see clearly

California-based Ocutrx Vision Technologies has developed an augmented reality (AR) headset that helps age-related macular degeneration (AMD) patients overcome severe and devastating vision loss.

July 9, 2019

Feature

Helius Medical rolling out PoNS treatment for mmTBI in Canada

Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) is transitioning from a development- to commercial-stage company as it rolls out its Health Canada-cleared PoNS medical device for the treatment of chronic balance...

July 2, 2019

Feature

Chardan president, Jonas Grossman, talks SPACs

By Abby Hardy As president of Chardan, an independent, global investment bank specializing in healthcare, disruptive technologies, and special purpose acquisition companies (SPACs), Jonas Grossman takes a worldwide view...

June 25, 2019

Ventripoint readies sales push of 3D heart imaging VMS+ 3.0 device

Spring Bank heading into data-rich 2020

Lobo Genetics enabling personalized cannabis product selection based on consumers’ genes

Soricimed’s platform of unique peptides making waves in cancer and beyond

Salarius Pharmaceuticals targeting epigenetic causes of cancers

KemPharm sees license deal, debt restructuring as transformative events

OncoSec TAVO technology aiming to reverse checkpoint inhibitor resistance

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

CytoDyn developing leronlimab (PRO140) as a pipeline in a drug

DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations

Interface Biologics sells Endexo surface modification business, sharpens focus on Epidel drug delivery platform

Precipio aims to prevent misdiagnosis of blood-related cancers

Beyond Air’s cylinder-free nitric oxide delivery system for respiratory conditions

PharmAust readies pivotal trial in Australia to treat cancer in dogs

Theralase Phase 2 NMIBC clinical study could support marketing application

Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH

PharmaCyte’s Cell-in-a-Box encapsulation technology targeting cancer, diabetes

Stifel analyst discusses emerging NASH therapeutic space

Ocutrx augmented reality headset helping AMD patients see clearly

Helius Medical rolling out PoNS treatment for mmTBI in Canada

Chardan president, Jonas Grossman, talks SPACs

General

More